7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid and Adenoma

7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid has been researched along with Adenoma in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bezawada, N; Chan, AT; Fuchs, CS; Giovannucci, EL; Mehta, RS; Milne, GL; Ogino, S; Song, M; Wu, K	1
Backman, V; Carolan, PJ; Chan, AT; Chin, SM; Chung, DC; Colizzo, FP; Drew, DA; Flagg, M; Freedman, M; Gala, M; Garber, JJ; Gilpin, KK; Huttenhower, C; Kedrin, D; Khalili, H; Kwon, DS; Markowitz, SD; Milne, GL; Nishioka, NS; Parziale, M; Pond, E; Rawlings, CA; Richter, JM; Roy, HK; Schuck, MM; Staller, K; Stewart, K; Wang, M	1
Cai, Q; Chen, Z; Milne, G; Ness, RM; Shrubsole, MJ; Smalley, WE; Wen, W; Zheng, W	1
Beauchamp, RD; Billheimer, DD; Coffey, RJ; Heslin, MJ; Johnson, JC; Joshi, PR; Merchant, NB; Morrow, JD; Ness, RM; Schmidt, CR; Schwartz, DA; Shrubsole, MJ; Washington, MK; Zheng, W	1

Trials

1 trial(s) available for 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid and Adenoma

Article	Year
ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. Trials, 2017, 02-01, Volume: 18, Issue:1 Topics: Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Boston; Carcinoma; Clinical Protocols; Colorectal Neoplasms; Cytokines; Disease Progression; Double-Blind Method; Female; Humans; Inflammation Mediators; Male; Middle Aged; Prospective Studies; Prostaglandins; Protective Factors; Research Design; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult	2017

Article

Year

ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial.

Trials, 2017, 02-01, Volume: 18, Issue:1

Topics: Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Boston; Carcinoma; Clinical Protocols; Colorectal Neoplasms; Cytokines; Disease Progression; Double-Blind Method; Female; Humans; Inflammation Mediators; Male; Middle Aged; Prospective Studies; Prostaglandins; Protective Factors; Research Design; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult

2017

Other Studies

3 other study(ies) available for 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid and Adenoma

Article	Year
Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs. Cancer prevention research (Philadelphia, Pa.), 2014, Volume: 7, Issue:7 Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents; Biomarkers, Tumor; Case-Control Studies; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Prognosis; Prospective Studies; Prostaglandins; Risk Factors	2014
Urinary prostaglandin E2 metabolite and risk for colorectal adenoma. Cancer prevention research (Philadelphia, Pa.), 2012, Volume: 5, Issue:2 Topics: Adenoma; Adult; Aged; Biomarkers, Tumor; Case-Control Studies; Colorectal Neoplasms; Cyclooxygenase 2; Dinoprostone; Female; Humans; Male; Middle Aged; Prognosis; Prostaglandins	2012
Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2006, Volume: 4, Issue:11 Topics: Adenoma; Aged; Biomarkers, Tumor; Colonic Polyps; Colorectal Neoplasms; Crohn Disease; Cyclooxygenase 2; Female; Humans; Immunohistochemistry; Logistic Models; Male; Middle Aged; Prostaglandins; Sensitivity and Specificity	2006